What are chemotherapeutic agents drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

chemotherapeutic agents drugs are pharmacologic agents that share a common mechanism (typically targeting PD-1). 0 are currently marketed, with 5 more in clinical development.

chemotherapeutic agents

0 marketed 4 in Phase 3 1 in Phase 2

This page covers all chemotherapeutic agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1, DNA, Microtubules and DNA.

Targets

PD-1 · DNA · Microtubules and DNA

Phase 3 pipeline (4)

docetaxel plus oxaliplatin and capecitabine · LiNing · Oncology
Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor.
epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil · Sun Yat-sen University · Oncology
Epirubicin, pirarubicin, and fluorouracil are anthracycline and antimetabolite chemotherapeutic agents that work by inhibiting DNA synthesis and inducing DNA damage, leading to cell death.
Tislelizumab plus Carboplatin and Paclitaxel · RemeGen Co., Ltd. · Oncology
Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.
carboplatin/cisplatin-etoposide · Shanghai Henlius Biotech · Oncology
Carboplatin and cisplatin-etoposide work by interfering with DNA replication in cancer cells, ultimately leading to cell death.

Phase 2 pipeline (1)

CCRT with weekly docetaxel & cisplatin · Samsung Medical Center · Oncology
Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death.

Patent intelligence

chemotherapeutic agents patent landscape — aggregated cliff calendar, attackable patents, originator estates